SCHEMBL3330577

SCHEMBL3330577

CC(C)(C)OC(=O)N1CCCC1C(=O)NC1CC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN4A P35499 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.57
NPC1 O15118 1/20 0.57
KDM4E B2RXH2 2/20 0.56
LMNA P02545 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HSD17B10 Q99714 1/20 0.54
MAPK1 P28482 1/20 0.52
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
ALDH1A1 P00352 1/20 0.51
EPHX1 P07099 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 2/20 0.47
SCN5A Q14524 1/20 0.46
SCN3A Q9NY46 1/20 0.46
USP30 Q70CQ3 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3330572 1.00 SCN4A (0.59) SCN4ASMN1; SMN2NPC1KDM4ELMNA
SCHEMBL3331101 0.96 SCN4A (0.58) SCN4ASMN1; SMN2NPC1KDM4ELMNA
SCHEMBL3331106 0.96 SCN4A (0.58) SCN4ASMN1; SMN2NPC1KDM4ELMNA
SCHEMBL7423990 0.94 KDM4E (0.61) SCN4ASMN1; SMN2NPC1KDM4ELMNA
SCHEMBL2449945 0.90 SCN4A (0.61) SCN4ASMN1; SMN2NPC1KDM4ELMNA
SCHEMBL2449941 0.90 SCN4A (0.61) SCN4ASMN1; SMN2NPC1KDM4ELMNA
SCHEMBL5403510 0.85 SMN1; SMN2 (0.60) SCN4ASMN1; SMN2NPC1KDM4ELMNA
SCHEMBL15307926 0.85 SMN1; SMN2 (0.60) SCN4ASMN1; SMN2NPC1KDM4ELMNA
SCHEMBL12057492 0.85 SMN1; SMN2 (0.60) SCN4ASMN1; SMN2NPC1KDM4ELMNA
SCHEMBL7422735 0.85 SMN1; SMN2 (0.60) SCN4ASMN1; SMN2NPC1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669266-B2 Quinoline-carboxamide derivatives as P2Y12 antagonists SANOFI (FR) 2014-03-11 US disclosed
US-20100135999-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-06-03 US disclosed
EP-2148871-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS Sanofi-Aventis (FR) 2010-02-03 EP disclosed
WO-2008128647-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100135999-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS P2RY12, P2RY1, P2RY2 SCN4A 1347/4885SMN1; SMN2 4406/4885NPC1 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.